Tepotinib Disease Interactions
There are 3 disease interactions with tepotinib.
Tepotinib (applies to tepotinib) ILD/pneumonitis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment
The use of tepotinib may cause interstitial lung disease (ILD)/pneumonitis, sometimes resulting in fatalities. Care should be exercised when using this drug in patients with preexisting pulmonary impairment. Tepotinib should be immediately withheld in patients with suspected ILD/pneumonitis and permanently discontinued if no other potential causes of ILD/pneumonitis are identified. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis.
Tepotinib (applies to tepotinib) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The use of tepotinib may cause hepatotoxicity, sometimes resulting in fatalities. No dosage modification is recommended in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) liver dysfunction. Care should be exercised when using tepotinib in patients with severe liver dysfunction (Child-Pugh C) as its pharmacokinetics and safety have not been studied in this patient population. It is recommended to monitor liver function tests (including ALT, AST, and total bilirubin) prior to the start of therapy, every 2 weeks during the first 3 months of therapy, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Tepotinib should be withheld, the dose should be reduced, or therapy should be permanently discontinued based on the severity of the adverse reaction.
Tepotinib (applies to tepotinib) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Care should be exercised when using tepotinib in patients with severe renal dysfunction (CrCl less than 30 mL/min) as the recommended dosage has not been established in this patient population. No dosage adjustment is recommended in patients with mild or moderate renal dysfunction (CrCl 30 to 89 mL/min).
Switch to professional interaction data
Tepotinib drug interactions
There are 289 drug interactions with tepotinib.
Tepotinib alcohol/food interactions
There is 1 alcohol/food interaction with tepotinib.
More about tepotinib
- tepotinib consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Taxol
Taxol (paclitaxel) is used to treat breast cancer, lung cancer, and ovarian cancer. Includes Taxol ...
Tagrisso
Tagrisso (osimertinib) may be used to treat adults with non-small cell lung cancer (NSCLC) whose ...
Nivolumab
Nivolumab (brand name Opdivo) is an immunotherapy treatment that treats many cancers, such as ...
Paclitaxel
Paclitaxel systemic is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.